Facts About IPF
IPF is a debilitating and fatal lung disease.
Search
220316_EMPA-KIDNEY_Media-Infographic_final.pdf
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Boehringer Ingelheim 2022 half year results
First half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline
Improving lives by providing better access to treatments
Our ‘Access to Healthcare’ initiative aims to extend support to underserved communities affected by Non-Communicable Diseases
Transforming pig farming through AI
With our livestock farming technology based on sound analytics, we are improving pig farm practices, producing healthier pigs and a better farm economy.
Finding the right inhaler for you
Living with a chronic respiratory disease can make life complicated. This discussion guide can be used to help start a conversation with a healthcare professional about inhaler choice.
The chronic nature of generalized pustular psoriasis
Understanding the impact of the physical and psychological symptoms of this chronic disease.
DCRI-collaboration-empact-mi
Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
Digital solution for individualized diabetes care
With Exandra™, we have developed a clinical decision support tool for diabetes care to make everyday life easier for healthcare professionals.
Partnering in Retinal Health
Our partnering interests in retinal diseases offer opportunities for collaboration to complement our pipeline and advance treatment and delivery.
Boehringer Ingelheim half-year results 2023
First half of 2023: Boehringer Ingelheim sees strong growth and expansion in key therapy areas
The little things
In 2009 Anna was diagnosed with scleroderma. For her, however, the disease is no reason to give up. On the contrary.
Diabetes
Diabetes
Partnership canine oncology
The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Our Vision
At Boehringer Ingelheim, we have expanded our global research and development activities to tackle eye diseases, specifically those affecting the back of the eye.
SPEVIGO (spesolimab) wins 2023 Prix Galien USA Award
SPEVIGO® (spesolimab) wins 2023 Prix Galien USA Best Orphan/Rare Diseases Solution Award
Dan
People with Type 2 diabetes (T2D) have an increased risk of heart disease
Patient Documentary
People with type 2 diabetes are two to four times more likely to develop heart disease compared with people without diabetes
World Rabies Day: BI fights rabies misconceptions
Boehringer Ingelheim joins efforts to fight rabies under this year’s theme for World Rabies Day to raise awareness of the disease and its prevention.
Retinal Health Research
Our research is targeting key mechanisms in the pathogenesis of retinal diseases – vascular dysfunction, neuronal dysfunction and neuronal inflammation.
We support non-linear career paths.
Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”
Feline diabetes: how to detect and treat it
What are the symptoms of diabetes in cats, and how do you manage this chronic disease? Find the answers here.
Two new claims for Nexgard range in EU and Australia
Boehringer Ingelheim expands the label claims of its NexGard® brands for the treatment of two severe skin diseases in dogs in the EU and in Australia.
Our mission in cardiovascular, renal, and metabolic care
Interconnected cardiovascular, renal, and metabolic diseases affect over 1 billion lives globally